Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Antiplatelet agents make a comeback in ST-elevation myocardial infarction.

Wiviott SD, de Lemos JA.

Am Heart J. 2007 Oct;154(4):603-6. No abstract available.

PMID:
17892976
2.

Future of oral antiplatelet therapy: four challenged hypotheses.

Serebruany VL, Makarov LM.

Thromb Haemost. 2009 Jun;101(6):1041-3. No abstract available.

PMID:
19492145
3.

[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].

Koziński M, Grześk G, Kubica J.

Kardiol Pol. 2012;70(2):206-12. Polish. No abstract available.

PMID:
22427098
4.

Ticagrelor--is there need for a new player in the antiplatelet-therapy field?

Schömig A.

N Engl J Med. 2009 Sep 10;361(11):1108-11. doi: 10.1056/NEJMe0906549. Epub 2009 Aug 30. No abstract available.

PMID:
19717845
5.

Role of ticagrelor in clopidogrel nonresponders: resistance is futile?

Tapp L, Shantsila E, Lip GY.

Circulation. 2010 Mar 16;121(10):1169-71. doi: 10.1161/CIR.0b013e3181d8d929. Epub 2010 Mar 1. No abstract available.

6.

Antiplatelet therapy in acute coronary syndromes.

Barker CM, Price MJ.

Curr Cardiol Rep. 2008 Jul;10(4):327-33.

PMID:
18611368
7.

Facts and controversies of aspirin and clopidogrel therapy.

Faxon DP, Freedman JE.

Am Heart J. 2009 Mar;157(3):412-22. doi: 10.1016/j.ahj.2008.11.019.

PMID:
19249409
8.

A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.

Wiviott SD, Braunwald E, Murphy SA, Antman EM; TRITON-TIMI 38 Investigators..

Am J Cardiol. 2008 May 1;101(9):1367-70. doi: 10.1016/j.amjcard.2008.03.016. Epub 2008 Apr 1. No abstract available.

PMID:
18435974
9.

Ticagrelor versus clopidogrel in acute coronary syndromes.

Cattaneo M.

N Engl J Med. 2009 Dec 10;361(24):2386; author reply 2387-8. No abstract available.

PMID:
20050197
10.

Prasugrel.

Wiviott SD, Antman EM, Braunwald E.

Circulation. 2010 Jul 27;122(4):394-403. doi: 10.1161/CIRCULATIONAHA.109.921502. Review. No abstract available.

11.

Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.

Orban M, Riegger J, Joner M, Tada T, Okrojek R, Hausleiter J, Kastrati A, Massberg S, Sibbing D.

Platelets. 2012;23(5):395-8. doi: 10.3109/09537104.2012.691189. Epub 2012 Jun 6. Erratum in: Platelets. 2012;23(5):398.

PMID:
22671583
12.

The role of antiplatelet therapy in the secondary prevention of coronary artery disease.

Behan MW, Chew DP, Aylward PE.

Curr Opin Cardiol. 2010 Jul;25(4):321-8. doi: 10.1097/HCO.0b013e328338f7b5. Review.

PMID:
20386440
13.

[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].

Grajek S.

Kardiol Pol. 2012;70(2):213-4. Polish. No abstract available.

PMID:
22427099
14.
15.

Controversies in acute cardiovascular care.

Taylor J.

Eur Heart J. 2014 Mar;35(9):535. No abstract available.

PMID:
24730030
16.

Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?

Graber MA, Dachs R, Darby-Stewart A.

Am Fam Physician. 2008 Dec 1;78(11):1252-3. Review. No abstract available.

17.

[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].

Neumann FJ.

MMW Fortschr Med. 2010 Apr 1;152(13):18. German. No abstract available.

PMID:
20443337
18.

"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?

Kern MJ.

Catheter Cardiovasc Interv. 2012 Feb 1;79(2):255-62. doi: 10.1002/ccd.24299. No abstract available.

PMID:
22271555
19.

For better or for worse: the future of antiplatelet therapy.

Alvarez W Jr.

Am J Health Syst Pharm. 2008 Jun 1;65(11):1017. doi: 10.2146/ajhp080115. No abstract available.

PMID:
18499873
20.

[Pharmazie in unserer Zeit 4/2009].

Alban S, Dingermann T.

Pharm Unserer Zeit. 2009;38(4):295. doi: 10.1002/pauz.200990042. German. No abstract available.

PMID:
19572344

Supplemental Content

Support Center